18. Sep 2026
Description
(AWP Alliance News) - Sandoz entered a licensing, development, manufacturing, commercialization agreement with mAbxience to collaborate on a proposed emicizumab biosimilar, now in early-stage development. Sandoz will receive exclusive global commercialization rights excluding Argentina, Uruguay, Paraguay.
The reference product, Hemlibra (emicizumab), generated an estimated USD 5.7 billion in global sales, making it a major new target for Sandoz's biosimilar pipeline. mAbxience will lead development, manufacturing, with financial terms kept confidential. The deal expands Sandoz's biosimilar pipeline to 40 assets.
https://www.publicnow.com/view/81C9955CD0D9A2BC440ABD9F7F8FF7C48D6CE2F3…
Disclaimer: This news brief was created using generative artificial intelligence. Sandoz Group AG published the original content used to generate this news brief via EQS News on September 18, 2026, and is solely responsible for the information contained therein.
